|2004N-0133 - Part 11 Public Meeting; June 11, 2004|
|FDA Comment Number :||EC19|
|Submitter :||Mr. Peter Robertson||Date & Time:||09/07/2004 07:09:04|
| Please see attached comments in response to the specific questions raised in the request for comments on Part 11 review.
AstraZeneca appreciates this opportunity to contribute to the discussion.